Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | CCR8 | P51685 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19153634 | 0.77 | ADORA2A (0.56) | ADORA2AADORA1CCR8KMT2AALDH1A1 | |
| SCHEMBL18238981 | 0.75 | CDK8 (0.37) | — | |
| SCHEMBL13024472 | 0.75 | ADORA2A (0.62) | ADORA2AADORA1CCR8KMT2AALDH1A1 | |
| SCHEMBL18238086 | 0.73 | ALDH1A1 (0.35) | ADORA2AADORA1ALDH1A1HSD17B10JAK2 | |
| SCHEMBL18237693 | 0.73 | KDM5B (0.33) | — | |
| SCHEMBL22643889 | 0.70 | PRMT5 (0.34) | — | |
| SCHEMBL18239041 | 0.69 | ALDH1A1 (0.45) | ADORA2AADORA1CCR8KMT2AALDH1A1 | |
| SCHEMBL19131803 | 0.66 | ADORA2A (0.50) | ADORA2AADORA1CCR8KMT2AALDH1A1 | |
| SCHEMBL18237951 | 0.66 | ADORA2A (0.39) | ADORA2AADORA1KMT2AALDH1A1KDM4E | |
| SCHEMBL2347240 | 0.65 | ADORA2A (0.36) | ADORA2AADORA1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | ADORA2A 4582/4885ADORA1 4484/4885CCR8 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.